Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA.
Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02627-17. Print 2018 Jun.
Fosfomycin is the only expoxide antimicrobial and is currently under development in the United States as an intravenously administered product. We were interested in identifying the exposure indices most closely linked to its ability to kill bacterial cells and to suppress amplification of less susceptible subpopulations. We employed the hollow fiber infection model for this investigation and studied wild-type strain PAO1. Because of anticipated rapid resistance emergence, we shortened the study duration to 24 h but sampled the system more intensively. Doses of 12 and 18 g/day and schedules of daily administration, administration every 8 h, and administration by continuous infusion for each daily dose were studied. We measured fosfomycin concentrations (by liquid chromatography-tandem mass spectrometry), the total bacterial burden, and the burden of less susceptible isolates. We applied a mathematical model to all the data simultaneously. There was a rapid emergence of resistance with all doses and schedules. Prior to resistance emergence, an initial kill of 2 to 3 log(CFU/ml) was observed. The model demonstrated that the area under the concentration-time curve/MIC ratio was linked to total bacterial kill, while the time that the concentration remained above the MIC (or, equivalently, the minimum concentration/MIC ratio) was linked to resistance suppression. These findings were also seen in other investigations with ( systems) and (murine system). We conclude that for serious infections with high bacterial burdens, fosfomycin may be of value as a new therapeutic and may be optimized by administering the agent as a continuous or prolonged infusion or by use of a short dosing interval. For indications such as ventilator-associated bacterial pneumonia, it may be prudent to administer fosfomycin as part of a combination regimen.
磷霉素是唯一的环氧化物抗菌药物,目前正在美国开发为静脉内给药产品。我们有兴趣确定与杀死细菌细胞和抑制敏感性较低的亚群扩增能力最密切相关的暴露指数。我们为此研究采用了中空纤维感染模型,并研究了野生型菌株 PAO1。由于预期会迅速产生耐药性,我们将研究时间缩短至 24 小时,但更密集地采样系统。研究了每天 12 克和 18 克的剂量以及每天给药、每 8 小时给药和连续输注每个每日剂量的方案。我们测量了磷霉素浓度(通过液相色谱-串联质谱法)、总细菌负荷和敏感性较低分离物的负荷。我们同时对所有数据应用了数学模型。所有剂量和方案都迅速出现了耐药性。在耐药性出现之前,观察到初始杀灭 2 到 3 对数(CFU/ml)。该模型表明浓度-时间曲线下面积/MIC 比值与总细菌杀灭有关,而浓度保持在 MIC 以上的时间(或等效地,最小浓度/MIC 比值)与耐药性抑制有关。在其他使用 (系统)和 (鼠系统)的研究中也观察到了这些发现。我们的结论是,对于高细菌负荷的严重感染,磷霉素作为一种新的治疗方法可能具有价值,通过连续或延长输注或使用短的给药间隔来优化该药物的给药。对于呼吸机相关细菌性肺炎等适应症,作为联合治疗方案的一部分使用磷霉素可能是谨慎的。